Wyeth Receives FDA Fast Track Designation For Its 13-valent Pneumococcal Conjugate Vaccine For Infants And Toddlers

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s investigational 13-valent pneumococcal conjugate vaccine for infants and toddlers. Wyeth is seeking a pediatric indication for active immunization against invasive pneumococcal disease (IPD) and otitis media caused by serotypes included in the vaccine.

More: continued here

Filed under: Infectious Diseases / Bacteria / Viruses on June 1st, 2008